USANA Health Sciences, Inc. (NYSE: USNA): Corporate Profile & Financials
Source: USANA Health Sciences, Inc. Form 10-K 2025
USANA Health Sciences, Inc. is a global health and wellness company that develops, manufactures, and markets science-based nutritional supplements, functional foods, and personal care and skincare products. The company’s core mission centers on promoting long-term health and cellular nutrition.
- Core Nutritional: Segment revenue: $775,452.
- Hiya Direct-To-Consumer: Segment revenue: $131,971.
- Other (Rise & Oola): Segment revenue: $17,834.
📋 Quick Facts / Company Snapshot: USANA Health Sciences (NYSE: USNA)
| Metric / Attribute | Disclosed Value / Fact |
|---|---|
| Official Company Name | USANA Health Sciences, Inc. |
| Stock Ticker & Exchange | NYSE: USNA |
| State of Incorporation | Utah |
| IRS Employer Identification No. | 87-0500306 |
| Corporate Headquarters | 3838 West Parkway Blvd., Salt Lake City, Utah 84120 |
| Telephone Number | (801) 954-7100 |
| Corporate Website | www.usana.com |
| Founder | Myron W. Wentz, Ph.D. |
| Year Founded | 1992 |
| Chief Executive Officer & Chairman | Kevin G. Guest |
| Chief Financial Officer | G. Douglas Hekking |
| Chief Operating Officer | Walter Noot |
| Chief Legal Officer & General Counsel | P. Joshua Foukas |
| Chief Scientific Officer | Kathryn Armstrong, Ph.D. |
| Worldwide Employee Count | Approximately 1,570 full-time equivalent employees (across 22 countries) |
| Core Active Customers | Approximately 387,000 (as of January 3, 2026) |
| Hiya Active Monthly Subscribers | Approximately 181,700 (as of January 3, 2026) |
| Global Geographic Presence | 25 markets worldwide |
| Key Proprietary Patent | U.S. Patent 10,632,101 (InCelligence complex formula) |
| Independent Public Auditor | KPMG LLP (Salt Lake City, Utah; Auditor Firm ID: 185) |
1. Corporate Identity: USANA Health Sciences Overview & History
The Big Picture
USANA Health Sciences, Inc. is a global health and wellness company that develops, manufactures, and markets science-based nutritional supplements, functional foods, and personal care and skincare products. The company’s core mission centers on promoting long-term health and cellular nutrition. Operating across 25 geographic markets globally, the company generates revenue through a combination of legacy direct selling channels and expanding direct-to-consumer and retail sales platforms.
For the fiscal year ended January 3, 2026, the company generated $925,257 thousand in net sales, supported by an international network of active Brand Partners, Preferred Customers, and direct-to-consumer subscribers. The company maintains an integrated business structure, conducting approximately 56% of its product manufacturing in-house through specialized facilities in the United States and China.
- Consolidated Net Sales (2025): $925,257 thousand
- Core Active Customers: Approximately 387,000 across global markets
- Hiya Active Monthly Subscribers: Approximately 181,700 customers
- Global Operating Footprint: 25 geographic markets worldwide
The Founders & Their Legacy
USANA was founded in 1992 by Myron W. Wentz, Ph.D., a scientist recognized for his work in cell culture technology and infectious disease diagnostics. Dr. Wentz established the enterprise with a primary focus on cellular health and maintenance through advanced nutritional science, translating biological research into commercial dietary formulations.
Dr. Wentz currently serves as an emeritus member of the Board of Directors and is no longer active in day-to-day corporate management. His founding vision continues to guide the company’s research and development philosophy, particularly regarding cellular nutrition and proprietary formulation development.
The Journey: History & Evolution
Since its establishment in Utah in 1992, USANA has expanded from a domestic direct selling enterprise into an international manufacturer operating across Asia Pacific, Europe, and the Americas. Early international expansion targeted key markets in the Asia Pacific region, leading to the acquisition of BabyCare Holdings, Ltd. in China to establish a local manufacturing and direct selling foundation.
In recent years, the company has undertaken strategic business acquisitions to diversify its distribution channels beyond traditional direct sales. In 2022, USANA acquired Rise Bar Wellness, Inc. and Oola Global, LLC. On December 23, 2024, USANA completed the acquisition of a 78.85% controlling interest in Hiya Health Products, LLC, establishing a presence in the direct-to-consumer pediatric health and wellness market.
- 1992: Founded in Utah by Dr. Myron W. Wentz with a focus on cellular nutrition
- 2010: Expanded Chinese footprint through the acquisition of BabyCare Holdings, Ltd.
- 2020: Awarded U.S. Patent 10,632,101 for the proprietary USANA InCelligence formulation
- 2022: Acquired Rise Bar Wellness, Inc. and Oola Global, LLC to expand food and personal development lines
- 2024: Acquired a 78.85% controlling interest in Hiya Health Products, LLC for $206,074 thousand net consideration
The Corporate Umbrella
USANA Health Sciences, Inc. serves as the ultimate parent corporation for a multi-jurisdictional network of operating subsidiaries. Primary operations in Mainland China are organized under BabyCare Holdings, Ltd., operating under direct selling authorizations granted by local provincial and municipal authorities.
Direct-to-consumer and specialized food manufacturing operations are held under distinct corporate entities, including Hiya Health Products, LLC, Rise Bar Wellness, Inc., and Oola Global, LLC. These businesses operate through commercial channels that complement the primary direct selling business model.
2. The Business Engine: USANA Health Sciences Business Model & Revenue Segments
The Core Divisions
USANA structures its business into two primary reportable operating segments—Core Nutritional and Hiya Direct-to-Consumer—alongside an “Other” category containing Rise Bar Wellness, Inc. and Oola Global, LLC. Segment operating performance is evaluated by the Chief Operating Decision Maker (CODM) based on earnings from operations before intersegment eliminations and tax allocations.
| Segment / Division | 2025 Net Sales ($ in thousands) | Cost of Sales ($ in thousands) | Brand Partner Incentives ($ in thousands) | SG&A Expense ($ in thousands) | Segment Earnings (Loss) from Operations ($ in thousands) |
|---|---|---|---|---|---|
| Core Nutritional | $775,452 | $141,847 | $335,631 | $244,614 | $40,507 |
| Hiya Direct-to-Consumer | $131,971 | $46,384 | $0 | $82,181 | $3,406 |
| Other (Rise & Oola) | $17,834 | $12,621 | $540 | $10,577 | $(6,481) |
| Consolidated Total | $925,257 | $200,852 | $336,171 | $337,372 | $37,432 |
The Core Nutritional segment generates the majority of revenue and incurs Brand Partner incentives expenses to compensate its independent sales force. The Hiya Direct-to-Consumer segment operates without Brand Partner incentives, directing a higher proportion of expenditure toward marketing, customer acquisition, and selling costs.
In 2025, the Core Nutritional segment recorded $6,390 thousand in goodwill impairment within its Buy-Sell reporting unit and $6,463 thousand in cost realignment charges. The “Other” category recorded $577 thousand in goodwill and amortizable intangible asset impairments.
The Global Product Catalog
USANA manufactures and distributes dietary supplements, functional foods, personal care, and pediatric health products. Products are classified into distinct health categories designed for specific metabolic, biological, or lifestyle functions.
| Product Category | Primary Description & Purpose | Core Sales Share (2025) | Core Sales Share (2024) | Core Sales Share (2023) |
|---|---|---|---|---|
| USANA® Optimizers | Targeted supplements supporting cardiovascular, skeletal, structural, and digestive health (e.g., Proflavanol®, CoQuinone® 30, BiOmega-3™). | 71% | 71% | 71% |
| Essentials / CellSentials® | Core vitamin, mineral, and antioxidant base formulas providing general total body cellular nutrition across age groups. | 16% | 16% | 16% |
| Foods | Meal replacement shakes, snack bars, and energy products promoting weight management and hydration (e.g., Nutrimeal, RESET™ program). | 6% | 6% | 7% |
| Personal Care & Skincare | Science-based personal care and Celavive® skincare systems formulated using USANA InCelligence Technology®. | 6% | 6% | 5% |
| All Other (Core) | Sales kits, business materials, product brochures, and branded promotional items for Brand Partners. | 1% | 1% | 1% |
In the Hiya Direct-to-Consumer segment, the product portfolio focuses on pediatric health products. For 2025, product sales contributions within Hiya comprised Kids Daily Multivitamin (54%), Kids Daily Probiotic (14%), Kids Daily Greens & Superfoods (13%), Kids Bedtime Essentials (11%), Kids Daily Iron (4%), Kids Daily Immune (3%), and Kids Daily Hydration (1%).
The Names You Know
USANA maintains proprietary product lines that account for significant portions of total consolidated net sales. The company owns 34 registered trademarks with the U.S. Patent and Trademark Office alongside international registrations.
| Key Product / Brand | 2025 Consolidated Sales Share | 2024 Consolidated Sales Share | 2023 Consolidated Sales Share |
|---|---|---|---|
| Hiya Multivitamins | 10% | N/A | N/A |
| USANA Essentials / CellSentials | 9% | 10% | 10% |
| Proflavanol | 8% | 10% | 10% |
| Probiotic | 7% | 8% | 9% |
USANA holds U.S. Patent 10,632,101 for its InCelligence complex formulation, which provides cellular signaling technology used in CellSentials and Celavive skincare product lines.
Mapping the Global Reach
The company classifies its international operations into two main geographic regions: Asia Pacific (further divided into Greater China, Southeast Asia Pacific, and North Asia) and Americas and Europe.
| Geographic Region / Market | 2025 Net Sales ($ in thousands) | 2024 Net Sales ($ in thousands) | 2023 Net Sales ($ in thousands) | 2025 Long-Lived Assets ($ in thousands) | 2024 Long-Lived Assets ($ in thousands) | Latest YoY (%) |
|---|---|---|---|---|---|---|
| Greater China | $424,541 | $457,976 | $475,099 | $32,577 | $31,668 | -7.30% |
| Southeast Asia Pacific | $131,996 | $146,795 | $163,890 | $16,737 | $13,893 | -10.08% |
| North Asia | $70,627 | $78,214 | $101,446 | $7,467 | $8,820 | -9.70% |
| Asia Pacific Subtotal | $627,164 | $682,985 | $740,435 | $56,781 | $54,381 | -8.17% |
| Americas and Europe | $298,093 | $171,518 | $180,575 | $80,304 | $83,460 | +73.80% |
| Consolidated Total | $925,257 | $854,503 | $921,010 | $137,085 | $137,841 | +8.28% |
Individual national markets contributing 10% or more of consolidated net sales include Mainland China ($381,816 thousand in 2025; $413,471 thousand in 2024) and the United States ($224,890 thousand in 2025; $91,796 thousand in 2024, inclusive of Hiya and Rise operations).
- Mainland China Net Sales (2025): $381,816 thousand (41.27% of consolidated sales)
- United States Net Sales (2025): $224,890 thousand (24.31% of consolidated sales)
- South Korea Net Sales (2025): $68,856 thousand
- International Net Sales Share: 75.7% of total consolidated sales generated outside the U.S.
The Brick & Mortar Footprint
USANA owns and leases primary operational properties, manufacturing plants, and distribution centers globally to support its production and commercial functions.
| Facility Location | Facility Size (Sq. Ft.) | Ownership Status | Primary Operational Purpose |
|---|---|---|---|
| Salt Lake City, Utah (HQ) | 354,000 | Company-Owned | Corporate headquarters, main tableting, packaging, quality control, distribution, and global R&D labs. |
| Salt Lake City, Utah (Foods) | 54,000 | Company-Owned | In-house manufacturing facility for functional food products and powdered mixes. |
| Beijing, China | 350,000 | Company-Owned | State-of-the-art production and quality control facility supplying the Chinese market. |
| Tianjin, China | 31,000 | Company-Owned | Specialized manufacturing plant for skincare and cosmetic products sold in China. |
| Sydney, Australia | 45,000 | Company-Owned | Regional office and warehousing facility for Australia and New Zealand. |
In addition to owned real estate, USANA leases regional administrative offices, distribution warehouses, and retail customer service centers across its operating markets in Asia Pacific, Europe, and the Americas.
3. The Financial Health: USANA Health Sciences (FY 2025) Audited Financial Statements
Earnings, Expenses & Profits: USANA Health Sciences Income Statement
The consolidated statement of comprehensive income reflects total revenues, cost of sales, operating expenses, tax adjustments, and final net earnings attributable to the parent company.
| Consolidated Statement of Comprehensive Income | 2025 ($ in thousands) | 2024 ($ in thousands) | 2023 ($ in thousands) | Latest YoY (%) |
|---|---|---|---|---|
| Net sales | $925,257 | $854,503 | $921,010 | +8.28% |
| Cost of sales | $200,852 | $161,212 | $176,693 | +24.59% |
| Gross profit | $724,405 | $693,291 | $744,317 | +4.49% |
| Brand Partner incentives | $336,171 | $363,699 | $394,257 | -7.57% |
| Selling, general and administrative | $337,372 | $263,268 | $256,989 | +28.15% |
| Impairment | $6,967 | $0 | $0 | N/M |
| Cost realignment | $6,463 | $0 | $0 | N/M |
| Total operating expenses | $686,973 | $626,967 | $651,246 | +9.57% |
| Earnings from operations | $37,432 | $66,324 | $93,071 | -43.56% |
| Interest income | $2,415 | $11,319 | $9,637 | -78.66% |
| Interest expense | $(842) | $(281) | $(262) | +199.64% |
| Other, net | $2,522 | $(1,011) | $7 | N/M |
| Earnings before income taxes | $41,527 | $76,351 | $102,453 | -45.61% |
| Income taxes | $30,050 | $34,291 | $38,665 | -12.37% |
| Net earnings | $11,477 | $42,060 | $63,788 | -72.71% |
| Less: Net earnings attributable to redeemable noncontrolling interest | $717 | $30 | $0 | +2290.00% |
| Net earnings attributable to USANA | $10,760 | $42,030 | $63,788 | -74.40% |
Consolidated gross margin was 78.3% in 2025 compared to 81.1% in 2024, reflecting the lower gross margin structure of the acquired Hiya direct-to-consumer business relative to core direct selling operations. Operating margin decreased to 4.0% in 2025 from 7.7% in 2024, affected by goodwill and intangible impairments, one-time severance and cost realignment charges, and higher SG&A expenses.
The consolidated effective income tax rate increased to 72.4% in 2025 from 44.9% in 2024. This increase resulted from lower pre-tax earnings in the United States relative to foreign jurisdiction earnings, combined with valuation allowances on U.S. foreign tax credits and state research credits.
Assets, Debts & Equity: USANA Health Sciences Balance Sheet
The consolidated balance sheet summarizes USANA’s asset base, short- and long-term liabilities, noncontrolling equity obligations, and net equity structure.
| Consolidated Balance Sheet | As of January 3, 2026 ($ in thousands) | As of December 28, 2024 ($ in thousands) | Latest YoY (%) |
|---|---|---|---|
| Cash and cash equivalents | $158,380 | $181,768 | -12.87% |
| Inventories | $102,608 | $69,735 | +47.14% |
| Prepaid expenses and other current assets | $27,417 | $27,684 | -0.96% |
| Total current assets | $288,405 | $279,187 | +3.30% |
| Property and equipment, net | $94,383 | $94,565 | -0.19% |
| Goodwill | $137,962 | $144,168 | -4.30% |
| Intangible assets, net | $133,151 | $151,823 | -12.30% |
| Deferred tax assets | $27,209 | $19,644 | +38.51% |
| Other assets | $61,805 | $58,806 | +5.10% |
| Total assets | $742,915 | $748,193 | -0.71% |
| Accounts payable | $17,263 | $11,984 | +44.05% |
| Line of credit | $14,000 | $23,000 | -39.13% |
| Other current liabilities | $97,302 | $104,641 | -7.01% |
| Total current liabilities | $128,565 | $139,625 | -7.92% |
| Deferred tax liabilities | $4,892 | $4,073 | +20.11% |
| Other long-term liabilities | $23,186 | $18,163 | +27.66% |
| Total liabilities | $156,643 | $161,861 | -3.22% |
| Redeemable noncontrolling interest | $53,168 | $54,223 | -1.95% |
| Common stock ($0.001 par value) | $18 | $19 | -5.26% |
| Additional paid-in capital | $83,544 | $75,816 | +10.19% |
| Retained earnings | $465,720 | $478,944 | -2.76% |
| Accumulated other comprehensive loss | $(16,178) | $(22,670) | -28.64% |
| Total stockholders’ equity attributable to USANA | $533,104 | $532,109 | +0.19% |
| Total liabilities, redeemable noncontrolling interest, & equity | $742,915 | $748,193 | -0.71% |
The balance sheet maintains a total asset base of $742,915 thousand, supported by $158,380 thousand in cash and cash equivalents. Stockholders’ equity stood at $533,104 thousand as of January 3, 2026.
The company maintains a revolving credit facility with $14,000 thousand outstanding as of January 3, 2026, down from $23,000 thousand at the end of fiscal 2024. Redeemable noncontrolling interest of $53,168 thousand reflects the fair value option structure associated with the remaining 21.15% equity interest in Hiya Health Products, LLC.
Cash Flow & Capital Allocation: USANA Health Sciences Cash Flow Statement
The consolidated statement of cash flows tracks net operational cash creation, capital expenditures, corporate transactions, and financing activities.
| Consolidated Statement of Cash Flows | 2025 ($ in thousands) | 2024 ($ in thousands) | 2023 ($ in thousands) | Latest YoY (%) |
|---|---|---|---|---|
| Net cash provided by operating activities | $22,349 | $60,992 | $70,641 | -63.36% |
| Purchases of property and equipment | $(13,823) | $(10,073) | $(14,494) | +37.23% |
| Proceeds from sale of property and equipment | $3,905 | $64 | $15 | +6001.56% |
| Payments to acquire businesses, net of cash acquired | $0 | $(203,336) | $0 | -100.00% |
| Net hedging and acquisition adjustments | $(207) | $255 | $2,504 | N/M |
| Net cash used in investing activities | $(10,125) | $(213,090) | $(11,975) | -95.25% |
| Repurchase of common stock | $(27,507) | $(9,444) | $(11,599) | +191.26% |
| Net line of credit borrowings (payments) | $(9,000) | $22,220 | $792 | N/M |
| Tax withholdings for equity awards | $(2,347) | $(3,223) | $(3,092) | -27.18% |
| Distributions & contingent considerations | $(1,749) | $0 | $(338) | N/M |
| Net cash provided by (used in) financing activities | $(40,603) | $9,553 | $(14,237) | N/M |
| Effect of exchange rates on cash balances | $5,111 | $(6,193) | $(2,503) | N/M |
| Net change in cash, cash equivalents, & restricted cash | $(23,268) | $(148,738) | $41,926 | -84.36% |
| Ending cash, cash equivalents, & restricted cash | $161,240 | $184,508 | $333,246 | -12.61% |
Operating cash flow reached $22,349 thousand in 2025, down from $60,992 thousand in 2024. Primary drivers of this change included lower operational net earnings and inventory additions of $34,685 thousand.
Capital expenditures totaled $13,823 thousand in 2025, directed toward information technology modernization, software development, and facility upgrades. Financing cash outflows included $27,507 thousand dedicated to share repurchases and $9,000 thousand in net payments on the revolving credit facility.
Funding the Future: R&D and Expansion Spending
USANA funds internal research and development to maintain its product line across global markets. R&D spending totaled $10,693 thousand in 2025, $11,571 thousand in 2024, and $11,446 thousand in 2023.
| Contractual Obligation Category | Total ($ in thousands) | Less Than 1 Year ($ in thousands) | 1 – 3 Years ($ in thousands) | 3 – 5 Years ($ in thousands) | More Than 5 Years ($ in thousands) |
|---|---|---|---|---|---|
| Operating leases | $19,639 | $6,404 | $9,168 | $3,945 | $122 |
| Other commitments (IT, sponsorships, events) | $28,500 | $18,370 | $8,781 | $1,227 | $122 |
| Total Contractual Obligations | $48,139 | $24,774 | $17,949 | $5,172 | $244 |
As of January 3, 2026, the company held $3,858 thousand in unconditional purchase obligations related to information technology and corporate advertising contracts.
4. The Corporate Family Tree: USANA Health Sciences Subsidiaries & Acquisitions
Subsidiaries, Associates, & Shared Ventures
USANA conducts its international direct selling, manufacturing, and direct-to-consumer businesses through a network of operating subsidiaries.
| Subsidiary / Operating Entity | Primary Jurisdiction | Ownership Percentage | Core Business Purpose |
|---|---|---|---|
| BabyCare Holdings, Ltd. | Mainland China | 100.00% | Primary operating entity for direct selling, retail, and e-commerce distribution in China. |
| Hiya Health Products, LLC | United States | 78.85% | Direct-to-consumer pediatric health and wellness subscription enterprise. |
| Rise Bar Wellness, Inc. | United States | 100.00% | Manufacturer and retailer of protein bars, clear protein beverages, and nutrition products. |
| Oola Global, LLC | United States | 100.00% | Direct selling business delivering personal development and lifestyle product lines. |
Strategic Investments & Minority Stakes
In 2020, USANA made a $20,000 thousand minority equity investment in a privately held enterprise. This non-controlling holding is carried under the measurement alternative for equity securities without readily determinable fair values and is recorded within the “Other assets” line item on the balance sheet.
As of January 3, 2026, no qualitative impairment indicators or observable price adjustments were identified for this investment during the fiscal year.
5. Power & Control: USANA Health Sciences Executive Leadership & Ownership
The Brain Trust: Board of Directors & Executive Leadership
USANA’s executive officers manage operational functions, global commercial operations, legal affairs, scientific research, and financial reporting under the oversight of the Board of Directors.
| Name | Age | Current Corporate Role | Tenure & Professional Background Context |
|---|---|---|---|
| Kevin G. Guest | 63 | Chief Executive Officer & Chairman of the Board | Reassumed CEO role in January 2026; Chairman since May 2020. Holds a B.A. from Brigham Young University. |
| G. Douglas Hekking | 56 | Chief Financial Officer | CFO since May 2017. Holds a B.S. from Univ. of Utah and an M.B.A. from Brigham Young Univ. |
| Walter Noot | 60 | Chief Operating Officer | COO since October 2019; previously Chief Information Officer since 2016. Holds a B.S. from BYU. |
| P. Joshua Foukas | 50 | Chief Legal Officer, General Counsel & Secretary | Chief Legal Officer since 2018. Holds a B.A. from Univ. of Utah and a J.D. from Univ. of Idaho. |
| Paul A. Jones | 63 | Chief People Officer | CPO since 2021; previously Chief Leadership Development Officer. Holds degrees from Utah State and Univ. of Phoenix. |
| Kathryn Armstrong, Ph.D. | 45 | Chief Scientific Officer | CSO since January 2025; EVP of R&D since July 2024. Holds a Ph.D. in Biochemistry from Notre Dame. |
| Brent Neidig | 42 | Chief Commercial Officer | Chief Commercial Officer since July 2023; previously Managing Director of China operations. Holds B.S. and M.B.A. from Univ. of Utah. |
The Board of Directors is chaired by Kevin G. Guest and includes independent directors Gilbert A. Fuller (85), Xia Ding (55), Peggie J. Pelosi (70), Frederic J. Winssinger (57), Timothy Wood (77), John T. Fleming (82), and J. Scott Nixon (66).
Who Owns the Stock?
As of January 3, 2026, USANA had 18,281 thousand shares of common stock issued and outstanding. The company’s equity ownership includes a significant concentration held by its founder’s holding entity.
- Gull Global, Ltd. Ownership: 40.0% of total outstanding common stock (7,308 thousand shares)
- Control Entity Details: Gull Global, Ltd. is solely owned and controlled by founder Dr. Myron W. Wentz
- Non-Affiliate Public Float Market Value: Approximately $328 million (as of June 27, 2025)
- Outstanding Common Share Count: 18,456,935 shares (as of March 13, 2026)
6. Strategic Outlook: USANA Health Sciences Growth Catalysts & Key Risks
Competitive Advantages & Economic Moats
USANA’s operating model relies on several core capabilities: in-house manufacturing infrastructure, proprietary product development, a global commercial presence, and an expanding omni-channel distribution structure.
- In-House Manufacturing Control: Approximately 56% of total product sales manufactured in company facilities in Salt Lake City, Beijing, and Tianjin.
- Proprietary Research & Patent Protection: Formulation development supported by internal labs and U.S. Patent 10,632,101 (InCelligence Complex).
- Omni-Channel Distribution Footprint: Multi-channel structure spanning direct sales, direct-to-consumer subscriptions (Hiya), third-party online marketplaces, and retail placements (Rise).
- Integrated Global Compensation Model: Seamless international Compensation Plan (excluding Mainland China) supporting global Brand Partner networks.
What Could Go Wrong? Key Challenges & Business Risks
USANA operates in highly regulated global markets and faces operational, legal, tax, and commercial risks across its operating segments.
- Regulatory Risks in Direct Selling: Direct sales programs are subject to regulatory oversight by agencies such as the U.S. Federal Trade Commission (FTC) and China’s State Administration of Market Regulation (SAMR).
- Geographic Concentration in Greater China: Greater China represented 45.9% of consolidated net sales in 2025. Changes in regulatory policies, licensing rules, or consumer sentiment in China could impact sales performance.
- Active Customer Base Fluctuations: Core Nutritional active Customer counts decreased 14.8% year-over-year in 2025 to 387,000.
- Digital Marketing & Customer Acquisition Costs: The Hiya segment relies on digital advertising channels and algorithm stability to acquire subscribers.
- Effective Tax Rate Disparity: Structural misalignment between international revenues (75.7% foreign) and domestic administrative costs contributed to an effective tax rate of 72.4% in 2025.
The Next Chapter: Growth & Expansion Initiatives
Management’s business strategy focuses on modernizing core nutritional operations while expanding channel diversification through acquired brands.
- Brand Partner Compensation Plan Enhancements: Modernized commission and bonus rules implemented in Q3 2025 to encourage sales volume and customer retention.
- Hiya International & Retail Expansion: Extending Hiya’s subscriber model into Canada and the United Kingdom in early 2026, alongside retail store launches starting in Q2 2026.
- In-House Production Integration: Transitioning select Hiya gummy and powdered formulations to USANA’s Salt Lake City facilities in the second half of 2026.
- Rise Retail Distribution Expansion: Expanding retail channel penetration for Rise clear protein beverages and protein bars with major retail accounts.
- India Market Development: Growing operations in India following market entry in late 2023 through product line additions and affiliate program rollouts.
The Verdict: Strategic Outlook & Conclusion
USANA Health Sciences is expanding beyond its legacy direct selling model into a broader health and wellness platform. The company’s financial structure features strong balance sheet cash reserves ($158,380 thousand) and operational cash generation ($22,349 thousand), offsetting recent declines in Core Nutritional customer numbers and increased income tax burdens.
The integration of Hiya Health Products, LLC provides direct-to-consumer revenue stream growth ($131,971 thousand in 2025) and higher retail channel engagement. Long-term execution depends on stabilizing Core Nutritional sales in Greater China, managing digital acquisition costs at Hiya, realizing manufacturing integration efficiencies, and successfully implementing updated Brand Partner incentive programs worldwide.
❓ Frequently Asked Questions: USANA Health Sciences, Inc.
What was USANA Health Sciences, Inc.’s revenue and net income in FY 2025?
In FY 2025 Ended Jan 3, 2025, USANA Health Sciences, Inc. (NYSE: USNA) reported total revenue of $925.26 M ((▲ 8.3%) compared to $854.50 M in the prior fiscal year). Gross profit stood at $724.40 M (gross margin of 78.29 %). Operating profit was $37.43 M and bottom-line net income was $11.48 M.
Is USANA Health Sciences, Inc. profitable and generating positive cash flow in FY 2025?
Yes, USANA Health Sciences, Inc. was profitable in FY 2025, recording net profit of $11.48 M (PAT margin: 1.24 %). On a cash basis, the company generated $22.35 M in cash flow from operating activities and invested $13.82 M in capital expenditures, resulting in free cash flow of $8.53 M. Return on Equity (ROE) was 2.15 % and Cash ROE was 4.19 %.
How much debt, assets, and equity does USANA Health Sciences, Inc. hold?
As of FY 2025 Ended Jan 3, 2025, USANA Health Sciences, Inc. held $742.91 M in total assets, $156.64 M in total liabilities, and $533.10 M in total stockholders’ equity. Net working capital was $159.84 M with a current ratio of 2.24x.
Who is the CEO and CFO of USANA Health Sciences, Inc.?
The Chief Executive Officer (CEO) of USANA Health Sciences, Inc. is Kevin G. Guest. The Chief Financial Officer (CFO) is G. Douglas Hekking.
Where is USANA Health Sciences, Inc. headquartered and when was it founded?
USANA Health Sciences, Inc. is headquartered in 3838 West Parkway Blvd., Salt Lake City, Utah 84120. The company traces its founding/incorporation to Utah. Total disclosed workforce/headcount is Approximately 1,570 full-time equivalent employees (across 22 countries). Its official corporate website is www.usana.com.
Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.